These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 35278260)

  • 1. Early clinical experience with nirmatrelvir/ritonavir for the treatment of COVID-19 in solid organ transplant recipients.
    Salerno DM; Jennings DL; Lange NW; Kovac DB; Shertel T; Chen JK; Hedvat J; Scheffert J; Brown RS; Pereira MR
    Am J Transplant; 2022 Aug; 22(8):2083-2088. PubMed ID: 35278260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adaptative Strategy of Immunosuppressive Drugs Dosage Adjustments When Combined With Nirmatrelvir/Ritonavir in Solid Organ Transplant Recipients With COVID-19.
    Boland L; Devresse A; Monchaud C; Briol S; Belaiche S; Giguet B; Couzi L; Thaunat O; Esposito L; Meszaros M; Roussoulieres A; Haufroid V; Le Meur Y; Lemaitre F
    Transpl Int; 2024; 37():12360. PubMed ID: 38596505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of nirmatrelvir/ritonavir on tacrolimus levels in lung transplant recipients: A single-center study.
    Wang X; Du W; Zhang D; Chen W; Zuo X
    Pulm Pharmacol Ther; 2024 Mar; 84():102280. PubMed ID: 38065402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing the use of nirmatrelvir/ritonavir in solid organ transplant recipients with COVID-19: A review of immunosuppressant adjustment strategies.
    Tang Y; Li Y; Song T
    Front Immunol; 2023; 14():1150341. PubMed ID: 37081880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-drug interactions of ritonavir-boosted SARS-CoV-2 protease inhibitors in solid organ transplant recipients: experience from the initial use of lopinavir-ritonavir.
    Gonzalez-García R; Roma JR; Rodríguez-García M; Arranz N; Ambrosioni J; Bodro M; Castel MÁ; Cofan F; Crespo G; Diekmann F; Farrero M; Forner A; LLigoña A; Marcos MÁ; Moreno A; Ruiz P; Soy D; Brunet M; Miró JM; Tuset M
    Clin Microbiol Infect; 2023 May; 29(5):655.e1-655.e4. PubMed ID: 36641051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management and Outcome of COVID-19 Infection Using Nirmatrelvir/Ritonavir in Kidney Transplant Patients.
    Giguère P; Deschenes MJ; Van Loon M; Hoar S; Fairhead T; Pazhekattu R; Knoll G; Karpinski J; Parikh N; McDougall J; McGuinty M; Hiremath S
    Clin J Am Soc Nephrol; 2023 Jul; 18(7):913-919. PubMed ID: 37099447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of nirmatrelvir/ritonavir on calcineurin inhibitor levels: Early experience in four SARS-CoV-2 infected kidney transplant recipients.
    Wang AX; Koff A; Hao D; Tuznik NM; Huang Y
    Am J Transplant; 2022 Aug; 22(8):2117-2119. PubMed ID: 35158412
    [No Abstract]   [Full Text] [Related]  

  • 8. "Saving lives with nirmatrelvir/ritonavir one transplant patient at a time".
    Belden KA; Yeager S; Schulte J; Cantarin MPM; Moss S; Royer T; Coppock D
    Transpl Infect Dis; 2023 Apr; 25(2):e14037. PubMed ID: 36847419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of nirmatrelvir/ritonavir and tacrolimus interaction in kidney transplant recipients infected by COVID-19: a three-case series.
    Guzmán Cordero C; Saez-Torres de Vicente M
    Eur J Hosp Pharm; 2024 Feb; 31(2):175-177. PubMed ID: 36535689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nirmatrelvir/ritonavir treatment in SARS-CoV-2 positive kidney transplant recipients - a case series with four patients.
    Schneider J; Wobser R; Kühn W; Wagner D; Tanriver Y; Walz G
    BMC Nephrol; 2023 Apr; 24(1):99. PubMed ID: 37061677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nirmatrelvir/ritonavir Use With Tacrolimus in Lung Transplant Recipients: A Single-center Case Series.
    Dewey KW; Yen B; Lazo J; Seijo L; Jariwala R; Shah RJ; Quan D; Carpenter B; Paul Singer J; Breen K; Hays S; Florez R
    Transplantation; 2023 May; 107(5):1200-1205. PubMed ID: 36525555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effectiveness of nirmatrelvir/ritonavir regimen in hospitalized renal transplant patients with prolonged COVID-19 infection: a multicenter clinical experience.
    Zhang H; Wu W; Zheng Y; Fu Q; Chen P; Li J; Wu Z; Gu J; Li J; Liu L; Wu C; Long S; Xu B; Ling L; Fu Y; Wang C
    Ren Fail; 2024 Dec; 46(2):2385724. PubMed ID: 39282735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paxlovid (Nirmatelvir/Ritonavir) and Tacrolimus Drug-Drug Interaction in a Kidney Transplant Patient with SARS-2-CoV infection: A Case Report.
    Prikis M; Cameron A
    Transplant Proc; 2022; 54(6):1557-1560. PubMed ID: 35599203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
    Tönshoff B; Höcker B
    Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenytoin enzyme induction for management of supratherapeutic tacrolimus levels due to drug-drug interaction with nirmatrelvir/ritonavir: Case series and discussion.
    Marsh J; Logan AT; Bilgili EP; Bowman LJ; Webb AR
    Am J Health Syst Pharm; 2024 Jun; 81(13):e345-e352. PubMed ID: 38347740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
    Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcome in heart transplant recipients receiving everolimus in combination with dosage reduction of the calcineurin inhibitor cyclosporine A or tacrolimus.
    Fuchs U; Zittermann A; Ensminger SM; Schulz U; Gummert JF
    Transpl Immunol; 2014 Aug; 31(2):87-91. PubMed ID: 24932812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Three-Year Results From the Randomized SCHEDULE Study.
    Andreassen AK; Andersson B; Gustafsson F; Eiskjaer H; Rådegran G; Gude E; Jansson K; Solbu D; Karason K; Arora S; Dellgren G; Gullestad L;
    Am J Transplant; 2016 Apr; 16(4):1238-47. PubMed ID: 26820618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COVID-19 therapeutics and outcomes among solid organ transplant recipients during the Omicron BA.1 era.
    Hedvat J; Lange NW; Salerno DM; DeFilippis EM; Kovac D; Corbo H; Chen JK; Choe JY; Lee JH; Anamisis A; Jennings DL; Codispodo G; Shertel T; Brown RS; Pereira MR
    Am J Transplant; 2022 Nov; 22(11):2682-2688. PubMed ID: 35801839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nirmatrelvir-ritonavir for COVID-19.
    McDonald EG; Lee TC
    CMAJ; 2022 Feb; 194(6):E218. PubMed ID: 35115376
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.